Last updated: September 8, 2026
DARZALEX FASPRO is the subcutaneous formulation of daratumumab, marketed by Johnson & Johnson through Janssen in collaboration with Genmab. Its rapid adoption has shifted daratumumab demand away from intravenous DARZALEX and strengthened the product’s position in multiple myeloma. Combined DARZALEX sales reached approximately $9.7 billion in 2023, up from about $8.0 billion in 2022, making the franchise one of Johnson & Johnson’s largest pharmaceutical assets.[1]
FASPRO benefits from broad use across newly diagnosed and relapsed or refractory multiple myeloma, a short administration time, combination-regimen flexibility, and limited near-term biosimilar competition. The principal long-term risks are class competition from BCMA-directed therapies, erosion of the underlying daratumumab patent estate after the late 2020s, and payer pressure as multiple myeloma treatment becomes more crowded.
What is DARZALEX FASPRO and how does it differ from intravenous DARZALEX?
DARZALEX FASPRO combines daratumumab with recombinant human hyaluronidase, marketed through Halozyme’s ENHANZE drug-delivery technology. The standard formulation contains 1,800 mg of daratumumab and 30,000 units of hyaluronidase-fihj in a 15 mL single-dose vial.[2]
| Attribute |
DARZALEX FASPRO |
Intravenous DARZALEX |
| Active antibody |
Daratumumab |
Daratumumab |
| Administration |
Subcutaneous abdominal injection |
Intravenous infusion |
| Typical administration time |
Approximately 3 to 5 minutes for injection, with monitoring |
Several hours initially, with shorter times after dose reduction |
| Delivery partner |
Halozyme ENHANZE technology |
None required |
| Primary commercial advantage |
Convenience, chair-time reduction, lower infusion burden |
Established formulation and use in patients for whom subcutaneous dosing is unsuitable |
| FDA approval |
May 2020 |
November 2015 |
FASPRO was approved in the United States in May 2020 for certain patients with newly diagnosed or relapsed or refractory multiple myeloma.[2] The formulation is used alone and in combinations with proteasome inhibitors, immunomodulators, corticosteroids, and other multiple myeloma therapies.
The commercial conversion from intravenous DARZALEX to FASPRO has been important because the switch generally preserves the clinical value of daratumumab while reducing administration time and treatment-center resource requirements.
How large is the DARZALEX FASPRO market?
The disclosed financial market size is generally reported for the combined DARZALEX franchise rather than FASPRO alone. Johnson & Johnson reported the following global sales:
| Fiscal year |
DARZALEX sales |
Year-over-year change |
| 2021 |
Approximately $6.0 billion |
Approximately 43% |
| 2022 |
Approximately $8.0 billion |
Approximately 33% |
| 2023 |
Approximately $9.7 billion |
Approximately 22% |
Sources: Johnson & Johnson annual reports.[1,3,4]
The exact FASPRO contribution is not separately disclosed in Johnson & Johnson’s public annual reporting. Market commentary and company disclosures indicate that FASPRO became the dominant administration format in the United States and several major markets after launch. The product’s economic value is therefore reflected in the combined DARZALEX revenue line, not in a separately reported FASPRO figure.
The growth profile has been driven by:
- Increased penetration of daratumumab in newly diagnosed multiple myeloma.
- Use in quadruplet and triplet regimens.
- Greater adoption of subcutaneous administration.
- Continued treatment of patients in relapsed or refractory settings.
- Expansion of survival-driven maintenance and combination treatment patterns.
- Growth in international markets.
The market is no longer dependent only on late-line rescue treatment. Earlier use in the treatment pathway has expanded the eligible population and increased duration of therapy.
What is the financial trajectory for DARZALEX FASPRO?
DARZALEX has moved from a high-growth launch product into a large-scale growth franchise. Revenue growth is expected to moderate as the global multiple myeloma market matures, but the franchise has several factors that can support continued sales expansion before material patent erosion.
Near-term trajectory
Near-term revenue is supported by the following factors:
-
Frontline treatment penetration. Newly diagnosed patients represent a larger commercial opportunity than late-line patients. Daratumumab has become embedded in several standard-of-care combinations.
-
Subcutaneous conversion. FASPRO improves treatment-center efficiency and patient convenience. This supports switching from intravenous DARZALEX without requiring a change in the core antibody therapy.
-
Combination breadth. Daratumumab can be paired with lenalidomide, bortezomib, pomalidomide, carfilzomib, dexamethasone, and other agents. That breadth creates multiple commercial pathways within the same disease.
-
Long treatment duration. Patients who respond and remain on therapy generate recurring revenue over multiple treatment cycles.
-
International expansion. Daratumumab has significant sales outside the United States, although pricing and access differ by country.
Medium-term trajectory
The principal medium-term issue is whether daratumumab retains a central role as BCMA-targeted therapies move earlier in the treatment sequence. CAR-T products and bispecific antibodies have demonstrated activity in heavily pretreated patients, but they do not fully replace daratumumab across all lines of therapy.
Daratumumab also has practical advantages over cellular therapies and some bispecifics:
- It does not require leukapheresis or individualized manufacturing.
- It can be administered in routine oncology settings.
- It has an established combination history.
- Its subcutaneous formulation reduces infusion-center burden.
- It is used broadly across treatment lines.
These advantages support continued use even as advanced therapies take share in later-line disease.
Which companies compete with DARZALEX FASPRO?
DARZALEX FASPRO competes with drugs and treatment platforms across several segments rather than with a single direct substitute.
| Competitor |
Company |
Mechanism or platform |
Competitive relevance |
| SARCLISA |
Sanofi |
Anti-CD38 antibody |
Direct antibody competitor |
| Empliciti |
Bristol Myers Squibb |
Anti-SLAMF7 antibody |
Earlier multiple myeloma biologic competitor, with a smaller commercial position |
| Carvykti |
Johnson & Johnson and Legend Biotech |
BCMA-directed CAR-T |
Later-line and increasingly earlier-line cellular therapy |
| Abecma |
Bristol Myers Squibb and 2seventy bio |
BCMA-directed CAR-T |
Later-line cellular therapy |
| Tecvayli |
Johnson & Johnson |
BCMA x CD3 bispecific antibody |
Relapsed or refractory disease |
| Elrexfio |
Pfizer |
BCMA x CD3 bispecific antibody |
Relapsed or refractory disease |
| Talvey |
Johnson & Johnson |
GPRC5D x CD3 bispecific antibody |
Relapsed or refractory disease |
| Lenalidomide generics |
Multiple manufacturers |
Immunomodulatory therapy |
Backbone therapy and payer pressure |
| Bortezomib generics |
Multiple manufacturers |
Proteasome inhibitor |
Backbone therapy and regimen economics |
The most direct branded antibody competitor is SARCLISA, but the greater strategic threat comes from BCMA-directed CAR-T therapies and bispecific antibodies. Those products may capture patients with refractory disease, especially when physicians prioritize deep responses after multiple prior therapies.
DARZALEX remains differentiated by its extensive clinical use, combination flexibility, and administration convenience.
What FDA approvals support the DARZALEX FASPRO franchise?
The FDA label covers multiple treatment settings, including:
- Newly diagnosed multiple myeloma in combination with other therapies.
- Patients eligible for autologous stem-cell transplant.
- Patients ineligible for transplant.
- Relapsed or refractory multiple myeloma.
- Certain light-chain amyloidosis patients in combination with cyclophosphamide, bortezomib, and dexamethasone.
The FDA’s approval of the subcutaneous formulation in 2020 materially improved the product’s operational profile.[2] DARZALEX FASPRO also reduced the treatment-center disadvantage that had previously affected intravenous daratumumab.
The label’s breadth creates commercial resilience. If one regimen loses share, use in another regimen can partially offset the decline.
What patents protect DARZALEX FASPRO?
DARZALEX FASPRO is protected by several potential layers of intellectual property:
-
Daratumumab antibody patents. These cover the anti-CD38 antibody, antibody sequences, binding characteristics, and related therapeutic uses.
-
Combination-treatment patents. These cover the use of daratumumab with immunomodulators, proteasome inhibitors, corticosteroids, or other multiple myeloma agents.
-
Subcutaneous formulation patents. These may cover the combination of daratumumab with hyaluronidase and the administration method.
-
Drug-delivery technology patents. Halozyme’s ENHANZE platform includes patents covering recombinant human hyaluronidase and subcutaneous delivery of biologic products.
-
Method-of-use patents. These may cover treatment schedules, patient populations, maintenance therapy, or specific combination regimens.
The core U.S. daratumumab composition patent is generally associated with expiration in the late 2020s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and jurisdiction-specific determinations. FASPRO may have later-expiring formulation, delivery, or method-of-use rights.
Because biologic patent protection is distributed across multiple patents and jurisdictions, the practical loss-of-exclusivity date cannot be determined from the active-ingredient patent alone.
When does DARZALEX lose exclusivity?
The commercial exclusivity timeline has several layers:
| Protection layer |
Expected commercial relevance |
| FDA biologic exclusivity |
Expired in the United States before the principal patent risks become decisive |
| Core daratumumab patents |
Generally late-2020s protection, subject to patent-term calculations |
| FASPRO formulation patents |
May extend beyond core antibody patents |
| ENHANZE delivery patents |
May create additional barriers to an equivalent subcutaneous product |
| Method-of-use patents |
Can complicate launch for specific indications even after composition patents expire |
| Biosimilar litigation |
Could delay or narrow launch depending on patent settlements and court outcomes |
The first competitive entry is more likely to involve a proposed daratumumab biosimilar than a conventional small-molecule generic. A biosimilar applicant would need to establish similarity to the reference product and could seek approval for some or all indications through the FDA’s 351(k) pathway.[5]
The existence of a biosimilar application would not automatically establish that the applicant can market an equivalent FASPRO product. The reference product, the delivery technology, the formulation, and the patent claims would each matter.
What is the Orange Book status of DARZALEX FASPRO?
DARZALEX FASPRO is a biologic, so its primary U.S. regulatory and patent framework is the Purple Book rather than the Orange Book. The Orange Book is principally used for approved small-molecule drugs and certain listed products. Biologic reference products and biosimilar applicants use the FDA’s Purple Book and the Biologics Price Competition and Innovation Act patent-dispute process.[5,6]
Paragraph IV certifications are therefore not the standard framework for a daratumumab biosimilar. A biosimilar applicant may provide a patent list, engage in the statutory patent-exchange process, and face patent litigation under the BPCIA.
Are there Paragraph IV challenges to DARZALEX FASPRO?
No conventional Paragraph IV challenge is the expected pathway for DARZALEX FASPRO because it is a biologic rather than an ANDA-listed small-molecule drug. Competitive risk would more likely arise through:
- A 351(k) biosimilar application.
- BPCIA patent litigation.
- A reference-product patent challenge.
- A non-infringement or invalidity position involving formulation or delivery patents.
- A competing antibody with its own biologic license application.
Publicly disclosed information through mid-2024 did not establish a major commercial daratumumab biosimilar launch or a market-changing settlement involving DARZALEX FASPRO.
How strong is the DARZALEX FASPRO patent estate?
The estate is commercially strong but not indefinite.
Strengths
- Multiple patent categories extend beyond the basic antibody claim.
- FASPRO combines an antibody with a specialized delivery system.
- The product has broad clinical use, creating method-of-use and combination patent opportunities.
- A biosimilar must address both the antibody and the reference-product presentation.
- The commercial franchise has substantial revenue that can support litigation and settlement strategies.
Weaknesses
- The core molecule has been commercially known for many years.
- Core composition protection is closer to expiry than launch-period protection.
- Some use patents may be vulnerable to validity or non-infringement challenges.
- Patent expiry in one major market can accelerate international pricing pressure.
- A biosimilar may initially target selected indications or a different presentation.
The most important question is whether later FASPRO and delivery patents can prevent a commercially meaningful biosimilar from entering after the main daratumumab patent expires. A narrow formulation patent may not fully protect the broader antibody franchise if a competitor develops a distinct subcutaneous presentation or pursues intravenous biosimilar entry first.
What generic or biosimilar launch scenarios exist?
Scenario 1: No meaningful biosimilar entry before the early 2030s
This would occur if the core patent estate, formulation protection, and litigation delay keep competitors out after the late-2020s. DARZALEX could continue to grow, but the growth rate would likely slow as the market matures.
Scenario 2: Intravenous daratumumab biosimilar entry first
A competitor could initially pursue intravenous daratumumab, leaving FASPRO with a convenience advantage. This scenario would create price pressure on the combined franchise but might not immediately eliminate the subcutaneous premium.
Scenario 3: Broad daratumumab biosimilar entry
A biosimilar with multiple indications and a competing delivery presentation would create the greatest risk. Payers could encourage substitution, particularly in maintenance or high-volume treatment settings.
Scenario 4: Formulation-protected FASPRO with antibody-level erosion
The intravenous product could face earlier price erosion while FASPRO retains a period of protected convenience and operational value. This would shift the franchise mix rather than produce an immediate collapse in total sales.
What patent litigation and settlement risks affect DARZALEX FASPRO?
The key litigation issues are likely to involve:
- Validity of daratumumab composition claims.
- Scope of claims covering subcutaneous administration.
- Ownership and licensing of hyaluronidase delivery technology.
- Patent-term adjustment and patent-term extension calculations.
- Infringement by a biosimilar formulation.
- Carve-outs for unpatented or non-protected indications.
- Settlement terms governing launch dates.
A settlement could permit an earlier biosimilar launch while preserving branded protection in selected indications or presentations. The economic effect would depend on the launch date, product scope, royalty obligations, and whether the biosimilar can substitute for FASPRO at the pharmacy or provider level.
What licensing deals support DARZALEX FASPRO?
Genmab discovered and developed daratumumab with Johnson & Johnson. Johnson & Johnson holds commercialization rights in major markets under its collaboration with Genmab, while Genmab receives milestone and royalty economics tied to DARZALEX sales.[7]
FASPRO also depends on Halozyme’s ENHANZE technology. That relationship gives Halozyme economic exposure to subcutaneous daratumumab and illustrates the importance of delivery-platform licensing in biologic lifecycle management.[8]
The financial structure creates three economic beneficiaries:
- Johnson & Johnson, which records the product sales.
- Genmab, which receives royalty and collaboration revenue.
- Halozyme, which receives payments tied to the licensed delivery technology.
What is the revenue exposure for Johnson & Johnson, Genmab, and Halozyme?
For Johnson & Johnson, DARZALEX is a major Innovative Medicine product. At approximately $9.7 billion in 2023 sales, it represented roughly 17% of the company’s pharmaceutical segment revenue, based on reported segment figures.[1]
For Genmab, DARZALEX royalties are a central source of recurring revenue and help fund its broader oncology pipeline. For Halozyme, FASPRO is one of the highest-profile commercial applications of the ENHANZE platform and validates the economic value of subcutaneous delivery technology.[7,8]
The exposure is asymmetric:
- Johnson & Johnson faces the largest absolute revenue risk from biosimilar erosion.
- Genmab faces royalty compression but retains a high-margin revenue stream.
- Halozyme faces risk tied to the specific delivery license but has a broader platform portfolio.
How does DARZALEX FASPRO compare with SARCLISA and BCMA therapies?
| Factor |
DARZALEX FASPRO |
SARCLISA |
BCMA CAR-T or bispecifics |
| Target |
CD38 |
CD38 |
BCMA |
| Administration |
Subcutaneous |
Primarily intravenous, depending on product and setting |
Cellular or subcutaneous/intravenous depending on product |
| Treatment setting |
Broad, including frontline and relapsed disease |
Primarily combination use in relapsed disease, with expansion potential |
Mostly later-line disease, with movement earlier |
| Operational burden |
Low relative to infusion and cellular therapy |
Higher infusion burden |
High for CAR-T; variable for bispecifics |
| Manufacturing model |
Off-the-shelf antibody |
Off-the-shelf antibody |
Patient-specific for CAR-T; manufactured biologic for bispecifics |
| Commercial maturity |
Established blockbuster |
Smaller direct competitor |
Rapidly expanding advanced-therapy segment |
DARZALEX FASPRO’s main advantage is breadth. Its main disadvantage is that it is an established target and may be less differentiated in patients who have become resistant to CD38-directed therapy.
Key Takeaways
- DARZALEX FASPRO is the subcutaneous form of daratumumab and has become the main growth driver within the DARZALEX franchise.
- Combined DARZALEX sales reached approximately $9.7 billion in 2023.
- FASPRO’s main commercial advantages are short administration time, lower treatment-center burden, and broad combination use.
- The product competes with SARCLISA, BCMA CAR-T therapies, bispecific antibodies, and low-cost backbone drugs.
- The core daratumumab patent estate is generally associated with late-2020s protection, while formulation, delivery, and method-of-use patents may extend later.
- DARZALEX FASPRO is governed by the Purple Book and BPCIA framework, not the conventional Orange Book Paragraph IV process.
- No major commercial daratumumab biosimilar launch had materially changed the market through mid-2024.
- Johnson & Johnson has the largest revenue exposure, while Genmab and Halozyme receive important royalty and technology-linked economics.
- The most likely erosion path is a staged shift: intravenous pressure first, followed by broader biosimilar risk to subcutaneous daratumumab.
FAQs
Is DARZALEX FASPRO a biosimilar?
No. DARZALEX FASPRO is an original subcutaneous formulation of daratumumab developed by Johnson & Johnson and Genmab. It is not a biosimilar to intravenous DARZALEX.
Does DARZALEX FASPRO use Halozyme technology?
Yes. The formulation uses recombinant human hyaluronidase-fihj associated with Halozyme’s ENHANZE delivery platform.
Can a biosimilar automatically replace DARZALEX FASPRO?
No. Biosimilar substitution depends on FDA designation, product presentation, state substitution rules, payer policy, and patent rights. A biosimilar to intravenous daratumumab would not necessarily be interchangeable with FASPRO.
What is the biggest commercial threat to DARZALEX FASPRO?
The largest long-term threat is combined pressure from daratumumab biosimilars and BCMA-directed therapies. BCMA products are more disruptive in later-line disease, while biosimilars present the clearest direct price risk.
Does Johnson & Johnson disclose FASPRO sales separately?
No. Johnson & Johnson generally reports sales for the combined DARZALEX franchise rather than breaking out intravenous DARZALEX and DARZALEX FASPRO as separate revenue lines.
References
- Johnson & Johnson. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2020). DARZALEX FASPRO prescribing information.
- Johnson & Johnson. (2023). 2022 annual report.
- Johnson & Johnson. (2022). 2021 annual report.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- Genmab A/S. (2024). Annual report 2023.
- Halozyme Therapeutics, Inc. (2024). 2023 annual report.
